Comparison 4.
Secondary outcome ‐ PGA 0/1
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Conventional systemic agents versus placebo | 3 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 1.1 Methotrexate | 2 | 283 | Risk Ratio (M‐H, Random, 95% CI) | 2.94 [1.47, 5.89] |
| 1.2 Fumaric acid esters | 1 | 704 | Risk Ratio (M‐H, Random, 95% CI) | 2.73 [1.72, 4.32] |
| 2 Conventional systemic 1 versus conventional systemic 2 | 1 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 2.1 Ciclosporin versus methotrexate | 1 | 88 | Risk Ratio (M‐H, Random, 95% CI) | 0.82 [0.47, 1.46] |
| 3 Anti‐TNF alpha versus placebo | 19 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 3.1 Etanercept versus placebo | 11 | 4334 | Risk Ratio (M‐H, Random, 95% CI) | 7.77 [5.98, 10.10] |
| 3.2 Adalimumab versus placebo | 7 | 3051 | Risk Ratio (M‐H, Random, 95% CI) | 8.38 [6.28, 11.18] |
| 3.3 Certolizumab versus placebo | 1 | 176 | Risk Ratio (M‐H, Random, 95% CI) | 35.88 [5.11, 251.73] |
| 4 Ustekinumab versus placebo | 8 | 4154 | Risk Ratio (M‐H, Random, 95% CI) | 11.33 [7.38, 17.39] |
| 5 Anti‐IL17 versus placebo | 15 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 5.1 Secukinumab versus placebo | 6 | 2607 | Risk Ratio (M‐H, Random, 95% CI) | 17.16 [7.48, 39.36] |
| 5.2 Ixekizumab versus placebo | 4 | 3268 | Risk Ratio (M‐H, Random, 95% CI) | 17.46 [9.87, 30.90] |
| 5.3 Brodalumab versus placebo | 5 | 4109 | Risk Ratio (M‐H, Random, 95% CI) | 18.78 [13.29, 26.55] |
| 6 Anti‐IL23 versus placebo | 4 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 6.1 Guselkumab versus placebo | 3 | 1502 | Risk Ratio (M‐H, Random, 95% CI) | 10.59 [7.73, 14.51] |
| 6.2 Tildrakizumab versus placebo | 1 | 355 | Risk Ratio (M‐H, Random, 95% CI) | 27.54 [3.95, 191.78] |
| 7 Other biologics | 2 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 7.1 Alefacept versus placebo | 1 | 507 | Risk Ratio (M‐H, Random, 95% CI) | 2.54 [1.22, 5.29] |
| 7.2 Itolizumab versus placebo | 1 | 225 | Risk Ratio (M‐H, Random, 95% CI) | 3.78 [0.94, 15.17] |
| 8 Biologic versus conventional systemic treatments | 3 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 8.1 Alefacept versus methotrexate | 1 | 212 | Risk Ratio (M‐H, Random, 95% CI) | 0.69 [0.37, 1.29] |
| 8.2 Infliximab versus methotrexate | 1 | 868 | Risk Ratio (M‐H, Random, 95% CI) | 1.99 [1.67, 2.37] |
| 8.3 Adalimumab versus methotrexate | 1 | 218 | Risk Ratio (M‐H, Random, 95% CI) | 2.44 [1.79, 3.32] |
| 9 Biologic 1 versus biologic 2 | 10 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 9.1 Ustekinumab versus etanercept | 1 | 903 | Risk Ratio (M‐H, Random, 95% CI) | 1.40 [1.24, 1.58] |
| 9.2 Secukinumab versus etanercept | 1 | 980 | Risk Ratio (M‐H, Random, 95% CI) | 2.09 [1.73, 2.53] |
| 9.3 Ixekizumab versus etanercept | 2 | 2209 | Risk Ratio (M‐H, Random, 95% CI) | 2.01 [1.74, 2.31] |
| 9.4 Secukinumab versus ustekinumab | 1 | 676 | Risk Ratio (M‐H, Random, 95% CI) | 1.23 [1.13, 1.35] |
| 9.5 Brodalumab versus ustekinumab | 2 | 3088 | Risk Ratio (M‐H, Random, 95% CI) | 1.17 [1.07, 1.27] |
| 9.6 Guselkumab versus adalimumab | 3 | 1658 | Risk Ratio (M‐H, Random, 95% CI) | 1.24 [1.17, 1.32] |
| 10 Small molecules versus placebo | 10 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 10.1 Apremilast versus placebo | 4 | 1776 | Risk Ratio (M‐H, Random, 95% CI) | 3.88 [2.04, 7.38] |
| 10.2 Tofacitinib versus placebo | 5 | 2838 | Risk Ratio (M‐H, Random, 95% CI) | 4.48 [3.51, 5.71] |
| 10.3 Ponesimod versus placebo | 1 | 326 | Risk Ratio (M‐H, Random, 95% CI) | 6.73 [2.19, 20.64] |
| 11 Biologic versus small molecules | 2 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 11.1 Etanercept versus tofacitinib | 1 | 998 | Risk Ratio (M‐H, Random, 95% CI) | 1.15 [1.04, 1.27] |
| 11.2 Etanercept versus apremilast | 1 | 166 | Risk Ratio (M‐H, Random, 95% CI) | 1.33 [0.78, 2.27] |